
    
      A randomized multi-center prospective study to compare the 12-month effectiveness (survival)
      and safety of erlotinib and pemetrexed as maintenance treatment in two groups of patients
      with locally advanced or metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) other
      than predominantly squamous cell histology, whose disease has not progressed immediately
      following platinum-based chemotherapy for 4 cycles administered per routine daily practice in
      each study center
    
  